low - Pre-revenue rare disease biotech with value driven entirely by clinical and regulatory milestones, not economic cycles. Dravet syndrome patients require treatment regardless of GDP growth. However, macro conditions affect: (1) ability to raise capital in risk-off environments, (2) acquisition appetite from large pharma partners, and (3) discount rates applied to future cash flows in DCF models. The 220% one-year return suggests momentum-driven trading amplified by biotech sector rotation.

Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (first potential revenue 2027-2028 post-approval). Clinical-stage biotechs are long-duration assets similar to zero-coupon bonds. Higher rates also increase financing costs for future capital raises, though current 6.53x current ratio and minimal debt (0.01 D/E) provide near-term insulation. The 10-year Treasury yield directly affects comparable biotech sector multiples and risk appetite for speculative growth stocks.

growth/momentum - Attracts speculative biotech investors focused on binary clinical catalysts and high-risk/high-reward profiles. The 220% one-year return and 70% six-month return indicate momentum-driven trading. Pre-revenue clinical-stage assets appeal to investors willing to underwrite 3-5 year timelines to commercialization with potential 5-10x returns on successful approval, but total loss on failure. Not suitable for value or income investors given negative cash flows and no dividend. Hedge funds and biotech-focused funds dominate ownership.